Ptc Therapeutics (PTCT) Retained Earnings (2012 - 2026)

Ptc Therapeutics' Retained Earnings history runs 15 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• In Q1 2026, Retained Earnings rose 100.3% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (up 100.3% YoY), while the FY2025 annual figure was $10.5 million, up 140.57% from the prior year.
• Retained Earnings was $8.5 million for Q1 2026 at Ptc Therapeutics, down from $10.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $10.5 million in Q4 2025 to a low of -$3.6 billion in Q3 2024.
• Historically, Retained Earnings has averaged -$1.9 billion across 5 years, with a median of -$2.7 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings plunged 242688.26% in 2024, then jumped 140.57% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$2.7 billion in 2022, then jumped by 99.95% to -$1.3 million in 2023, then sank by 1914.47% to -$25.9 million in 2024, then surged by 140.57% to $10.5 million in 2025, then dropped by 19.38% to $8.5 million in 2026.
• The last three Retained Earnings figures came in at $8.5 million (Q1 2026), $10.5 million (Q4 2025), and -$2.8 billion (Q3 2025), per Business Quant data.